NovoCure Limited Ordinary Shares (NVCR) News
Latest headlines that mention NVCR, newest first · each headline opens the original publisher
- Last price
- $15.55
- Day change
- -0.26%
- Next earnings
- 2026-10-29 BMO
NVCR headlines
latest coverageNovocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune. The post Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?' appeared first on Investor's Business Daily .
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Novocure stock slumped Thursday after the company's wearable medical device failed in patients with a form of brain cancer. The post Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer appeared first on Investor's Business Daily .
NVCR news alerts
Get an alert by email or push when a new headline mentions NVCR.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.